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he Yin and
ang of High-Density
ipoprotein Cholesterol*
acques Genest, MD, FAHA, FACC
ontreal, Quebec, Canada
igh-density lipoproteins (HDL) are fairly complex mac-
omolecules consisting of a core of hydrophobic lipids
cholesteryl esters and triglycerides), an envelope of phos-
holipids and some unesterified (free) cholesterol, and
polipoproteins (apo) that ensure structural integrity, serve
s ligands for protein (and possibly lipid) receptors, can act
s coactivators of enzymatic reactions, and are involved in
he cellular secretion of the lipoprotein. When the clinical
aboratory gives a report, it refers to the mass of cholesterol
ithin the specific particle (i.e., the HDL-C level). Rela-
ively little used is the measurement of serum apoA-I levels,
he major protein moiety of HDL particles, which may
eflect the number of circulating HDL particles. Given the
xtraordinary biological diversity of HDL particles, these
easurements, HDL-C and apoA-I levels, do not provide
uch functional information.
See page 634
Decades of research on the function of HDL have yielded
onsiderable insights and confusion. The cardioprotective
ffects of HDL seem to be multiple: prevention of low-
ensity lipoprotein oxidation and of vascular wall inflam-
ation and of thrombosis (1); preservation of endothelial
asomotor, proliferative, and survival functions (2); possible
revention of macrophage apoptosis (3); increase in endo-
helial progenitor cells (4); and the well-characterized role in
everse cholesterol transport. It is this latter mechanism (i.e.,
emoval of macrophage cholesterol from the plaque) that is
onsidered to be the most potent antiatherosclerotic mech-
nism of HDL.
Three decades ago, the first reports linking a low HDL-C
evel with the presence of coronary artery disease were
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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esearch Award in 2006 for work on the genetics of HDL.eported (5) and subsequently confirmed in multiple epide-
iologic studies. On the basis of these studies, the HDL-C
evel became a categorical cardiovascular risk factor in the
ational Cholesterol Education Program guidelines (6), but
ot a therapeutic target. This epidemiologic association was
hought to work in reverse: raising HDL should prevent
oronary artery disease. This simple paradigm remains
nproven to date.
With the molecular characterization of the major proteins
nvolved in HDL metabolism, the investigation of genetic
isorders of HDL identified 2 mutations challenging the
nce firmly held belief that with HDL-C, more was
etter. ApoA-IMilano, a naturally occurring variant of
poA-Iarg173cys, causes very low HDL-C levels without an
ncrease in coronary heart disease events (7); carriers of
he mutation seem to enjoy a healthy life. Mutations that
mpair the function of cholesteryl ester transfer protein
CETP) are associated with marked elevations in HDL-C
evels but not necessarily with protection against coronary
eart disease (8). The CETP inhibitors became the focus of
large drug discovery program in several pharmaceutical
ompanies. The first CETP inhibitor (compound JTT705)
sed in clinical trials produced elevations in HDL-C on the
rder of 35% at the highest (900-mg) dose. The second such
ompound, torcetrapib, proved toxic despite causing a large
ncrease in HDL-C levels and was withdrawn from clinical
se.
The study by van der Steeg et al. (9) in this issue of the
ournal combines data from a clinical study (the IDEAL
Incremental Decrease in Clinical Endpoints Through Ag-
ressive Lipid Lowering] trial) and the epidemiologic lon-
itudinal study EPIC Norfolk. The investigators examined
he risk of cardiovascular events at extreme levels of
DL-C, corrected (or not) for levels of apoA-I and apoB
as well as other covariates).
The significant and consistent finding is that in both
tudies (which differed in scope, intent, and populations),
levated levels of HDL-C are no longer cardioprotective
nd may confer additional risk once corrected for apoA-I
nd apoB levels. Interestingly, quartile analysis of the data
id not show this relationship of potential harm in high
DL-C levels; a similar finding was reported in the TNT
Treating to New Targets) study (10). This apparently
ounterintuitive finding may have important clinical impli-
ations: first, naturally occurring high levels of HDL-C may
ot protect against heart disease, and second, and herein lies
he most important and provocative finding, HDL-C as a
herapeutic goal may be fraught with potential dangers.
his was the case in the torcetrapib trials (Illuminate,
llustrate, Radiance 1 and 2) (11,12). One potential expla-
ation may be that large cholesterol-enriched HDL parti-
les lose some of their biological functions (cellular choles-
erol efflux via the adenosine binding cassette transporters
BCA1, ABCAG1; vascular endothelial vasomotor func-
ion modulation via SR-B1; antioxidant, antithrombotic,
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Editorial Comment February 12, 2008:643–4nd anti-inflammatory properties). The finding that
poA-I, even when corrected for HDL-C and apoB, re-
ains cardioprotective suggests that the means by which
DL particles are increased may be far more important
han the cholesterol mass in HDL particles.
These provocative findings must now be replicated in
ther large clinical and epidemiologic studies, there should
e an attempt to explain these findings in the laboratory,
nd finally, the development of HDL biomarkers (13)
hould be explored to assess clinically, rapidly, and reliably,
he many biological functions of HDL. This study raises
everal important issues.
s raising HDL beneficial in terms of cardiovascular
ealth? Clinical trials aimed at modifying lipids and li-
oprotein lipids have shown the unequivocal benefits of
educing low-density lipoprotein-C levels to reduce cardio-
ascular events. Commonly used drugs (statins and fibrates)
ave a modest (5% to 10%) effect on HDL-C, and this
ffect is of uncertain clinical significance. Niacin increases
DL-C by 25% to 35% but has been used in combination
herapy with other lipid-lowering drugs in most trials, and
vidence of unequivocal reduction in hard cardiovascular
nd points remains elusive. Presently, there are no data
howing unequivocally that raising HDL-C pharmacologi-
ally reduces cardiovascular risk.
oes the means by which this increase is achieved
atter? Given the multiple potentially beneficial effects of
DL on cardiovascular biology, there is scientific support
or the concept that raising small HDL particles (often
eferred to as “nascent” HDL particles) may be more
mportant than generating large, cholesterol-rich HDL
articles. Drugs that modulate HDL-C levels can be con-
eptually seen as those that decrease catabolism (CETP
nhibitors, possibly niacin) and those that increase the
roduction rate (fibrates and possibly small molecules that
ncrease apoA-I production, and agonists of the liver-
pecific receptor LxR to increase ABCA1-mediated choles-
erol efflux from cells). The latter category is presently under
re-clinical development. Although there are many theoret-
cal considerations to favor an increase in apoA-I (and
ascent HDL) production as a therapeutic target, clinical
rials will determine the appropriateness of this approach.
s HDL-C or apoA-I the appropriate measurement for
herapeutic goals? The HDL-C level is a time-honored
easurement, and subfractions (HDL3, HDL2) or apoA-I
ave not markedly increased, in large-population-based
tudies, our ability to discriminate between cases and con-
rols. Novel analytical techniques reveal that HDL particles
ontain over 50 different proteins (15). There is an increas-
ng need for the development of better analytical techniques
f HDL function and biomarkers of HDL particles. Basedn the study by van der Steeg et al. (9), the measurement of
poA-I will be an absolute necessity in clinical trials.
s HDL-C (simply) a marker of cardiovascular health?
roper life-style that includes no smoking, physical activity,
nd normal body weight are all associated with higher
DL-C levels and stand on their own merits with respect
o cardiovascular health.
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